Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo - PubMed (original) (raw)

Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo

S Alexandersen et al. J Virol. 1989 Jan.

Abstract

When mink kits were infected neonatally with a highly virulent strain of Aleutian disease virus (ADV), 100% of both Aleutian and non-Aleutian genotype mink died of interstitial pneumonia characterized by permissive ADV infection of alveolar type II cells. Treatment of infected kits with either mink anti-ADV gamma globulin or mouse monoclonal antibodies against ADV structural proteins reduced mortality by 50 to 75% and drastically reduced the severity of clinical signs. Interestingly, mink kits that survived the acute pulmonary disease all developed the chronic form of immune complex-mediated Aleutian disease. Thus, the antibodies directed against ADV structural proteins were capable of modulating the in vivo pathogenicity from an acute fulminant disease to a chronic immune complex-mediated disorder. The mechanism of this modulation was examined by strand-specific in situ hybridization. We found that the number of ADV-infected type II cells was the same in both untreated and antibody-treated kits. However, in the treated kits, viral replication and transcription were restricted at the cellular level. These data suggested that antibodies prevented acute viral pneumonia by restricting the intracellular level of viral replication and that the relevant antigenic determinants were contained within the viral structural proteins. The restricted levels of viral replication and transcription seen in antibody-treated mink kits resembled the levels observed in infected adult mink and suggested a role of antiviral antibodies in development of persistent infection and chronic immune complex disease.

PubMed Disclaimer

Cited by

Serum Analytes of American Mink (Neovison Vison) Challenged with Aleutian Mink Disease Virus.
Farid AH, Rupasinghe PP. Farid AH, et al. Animals (Basel). 2022 Oct 11;12(20):2725. doi: 10.3390/ani12202725. Animals (Basel). 2022. PMID: 36290111 Free PMC article.
Suppression of measles virus expression by noncytolytic antibody in an immortalized macrophage cell line.
Goldman MB, O'Bryan TA, Buckthal DJ, Tetor LM, Goldman JN. Goldman MB, et al. J Virol. 1995 Feb;69(2):734-40. doi: 10.1128/JVI.69.2.734-740.1995. J Virol. 1995. PMID: 7815537 Free PMC article.
AMDV Vaccine: Challenges and Perspectives.
Markarian NM, Abrahamyan L. Markarian NM, et al. Viruses. 2021 Sep 14;13(9):1833. doi: 10.3390/v13091833. Viruses. 2021. PMID: 34578415 Free PMC article. Review.
Epidemiology, pathogenesis, and diagnosis of Aleutian disease caused by Aleutian mink disease virus: A literature review with a perspective of genomic breeding for disease control in American mink (Neogale vison).
Vahedi SM, Salek Ardestani S, Banabazi MH, Clark F. Vahedi SM, et al. Virus Res. 2023 Oct 15;336:199208. doi: 10.1016/j.virusres.2023.199208. Epub 2023 Aug 28. Virus Res. 2023. PMID: 37633597 Free PMC article. Review.
Pathogenesis of Aleutian mink disease parvovirus infection: effects of suppression of antibody response on viral mRNA levels and on development of acute disease.
Alexandersen S, Storgaard T, Kamstrup N, Aasted B, Porter DD. Alexandersen S, et al. J Virol. 1994 Feb;68(2):738-49. doi: 10.1128/JVI.68.2.738-749.1994. J Virol. 1994. PMID: 8289377 Free PMC article.

References

1. J Infect Dis. 1968 Dec;118(5):510-26 - PubMed
1. Virology. 1967 Feb;31(2):238-47 - PubMed
1. J Immunol. 1972 Feb;108(2):555-7 - PubMed
1. Am J Pathol. 1973 May;71(2):331-44 - PubMed
1. Nature. 1975 Apr 3;254(5499):456-7 - PubMed

Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo - PubMed (original) (raw)